Compare · AZN vs EQ
AZN vs EQ
Side-by-side comparison of AstraZeneca PLC (AZN) and Equillium Inc. (EQ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and EQ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $563.07B, about 3215.0x EQ ($175.1M).
- Over the past year, AZN is down 3.5% and EQ is up 678.1% - EQ leads by 681.6 points.
- AZN has been more active in the news (21 items in the past 4 weeks vs 14 for EQ).
- AZN has more recent analyst coverage (25 ratings vs 11 for EQ).
- Company
- AstraZeneca PLC
- Equillium Inc.
- Price
- $181.67-2.33%
- $2.77-5.78%
- Market cap
- $563.07B
- $175.1M
- 1M return
- -0.57%
- +32.85%
- 1Y return
- -3.51%
- +678.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2018
- News (4w)
- 21
- 14
- Recent ratings
- 25
- 11
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Equillium Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest EQ
- Sr. Vice President and COO Zedelmayer Christine exercised 14,584 shares at a strike of $0.79 and sold $42,737 worth of shares (14,584 units at $2.93) as part of a pre-agreed trading plan (SEC Form 4)
- President and CSO Connelly Stephen sold $723,830 worth of shares (230,975 units at $3.13), decreasing direct ownership by 23% to 762,025 units (SEC Form 4)
- Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Principal Accounting Officer Tom Penny sold $191,750 worth of shares (65,000 units at $2.95) as part of a pre-agreed trading plan and exercised 65,000 shares at a strike of $0.79 (SEC Form 4)
- SEC Form 4 filed by Director Demski Martha J
- SEC Form 4 filed by Director Pruzanski Mark
- SEC Form 4 filed by CHAIRMAN Bradbury Daniel
- Sr. Vice President and COO Zedelmayer Christine sold $267,209 worth of shares (95,833 units at $2.79) as part of a pre-agreed trading plan and exercised 95,833 shares at a strike of $0.77 (SEC Form 4)
- SEC Form 4 filed by Director Mcdermott Charles Douglas
- SEC Form 4 filed by Director Troupin Barbara